Regeneron Pharmaceuticals Inc (REGN)vsBiomotion Sciences Ordinary Shares (SLXN)
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
SLXN
Biomotion Sciences Ordinary Shares
$1.34
+5.51%
HEALTHCARE · Cap: $5.20M
Smart Verdict
WallStSmart Research — data-driven comparison
REGN leads profitability with a 31.4% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 58/100 (C).
REGN
Buy58
out of 100
Grade: C
SLXN
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Margin of Safety
+99.9%
Fair Value
$2373.81
Current Price
$1.34
$2372.47 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bull Case : SLXN
The strongest argument for SLXN centers on Price/Book.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : SLXN
The primary concerns for SLXN are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
REGN carries more volatility with a beta of 0.40 — expect wider price swings.
REGN is growing revenue faster at 2.5% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (58/100 vs 23/100), backed by strong 31.4% margins. SLXN offers better value entry with a 99.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Biomotion Sciences Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Biomotion Sciences (SLXN) is an innovative biotechnology firm at the forefront of developing transformative therapies aimed at tackling severe and complex medical conditions. Specializing in regenerative medicine, the company boasts a promising pipeline of product candidates designed to enhance patient outcomes significantly. Backed by strategic collaborations that strengthen its research and development initiatives, Biomotion Sciences is positioned to capitalize on the growing demand for effective therapeutic solutions, making it a compelling investment opportunity in the dynamic biotechnology sector.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?